Avulux has received De Novo marketing authorisation from the FDA, establishing the first recognised device classification for ...
Erasca has been granted Fast Track Designation by the FDA for ERAS‑0015, an oral pan‑RAS molecular glue being developed for ...
FairJourney Bio has published a peer‑reviewed study in mAbs describing a novel antibody‑engineering approach designed to ...
AC Immune has announced encouraging preliminary findings from its phase 1 first‑in‑human study of ACI‑19764, an orally ...
Teva Pharmaceuticals has announced that the US Food and Drug Administration has accepted the new drug application for ...
VarmX has enrolled the first participant in its global phase 3 EquilibriX S trial evaluating VMX C001 for the rapid ...
The MHRA’s position is that MBMPs fall within the scope of the existing UK medicines regulatory framework set out in the ...
Lundbeck has secured orphan designation from the European Commission for asedebart, its investigational anti‑ACTH monoclonal ...
Unlike antibody drug conjugates, KJ‑103 does not contain a cytotoxic payload. It recruits immune cells to kill tumour cells ...
HUTCHMED has reported positive high‑level results from the Saffron phase 3 trial evaluating Orpathys (savolitinib) plus ...
Androlabs has appointed EffRx Pharmaceuticals as its commercial partner in Switzerland for Testavan, a testosterone ...
VarmX has enrolled the first participant in its global phase 3 EquilibriX S trial evaluating VMX C001 for restoring normal coagulation in patients taking FXa inhibitors who require an urgent surgery ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results